Cranmax® (Whole Cranberry Concentrate, Decas)

Vaccinium macrocarpon
Evidence Level
Limited
1 Clinical Trial
3 Documented Benefits
2/5 Evidence Score

Cranmax® is a whole-fruit cranberry (Vaccinium macrocarpon) concentrate from Decas Botanical Synergies, capturing the cranberry's juice, seeds, and skin. Cranberry is best known for supporting urinary tract health, largely through compounds that help keep bacteria from sticking to the bladder wall.

Studied Dose Commonly 500 mg of cranberry concentrate per day.
Active Compound Whole cranberry concentrate providing proanthocyanidins (PACs) and other cranberry polyphenols, with the bacterial anti-adhesion type-A PACs.

Benefits

Urinary tract health

Cranberry is widely used and studied for supporting urinary tract health and reducing the recurrence of urinary tract infections, a benefit recognized in reviews of non-antibiotic options.

Anti-adhesion action

Cranberry proanthocyanidins help stop certain bacteria from adhering to the bladder wall, the leading proposed mechanism for its urinary benefit.

Whole-fruit polyphenols

The whole fruit contains polyphenols that show antioxidant activity in laboratory tests. No human trial cited here has measured an antioxidant health outcome from this product.

Mechanism of action

1

Type-A proanthocyanidins

Cranberry's distinctive type-A PACs interfere with the fimbriae that E. coli use to stick to the urinary lining, helping bacteria be flushed out.

2

Whole-fruit polyphenols

Using the whole fruit provides a broad mix of polyphenols with antioxidant activity.

Clinical trials

1
Cranberry Among Non-Antibiotic Options: Overview of Systematic Reviews (women; not a Cranmax trial)
PubMed

Review of non-antibiotic interventions, including cranberry, to prevent recurrent urinary tract infections. (Santer et al. 2026, British Journal of General Practice)

Women aged 16 and over with recurrent UTIs.

This overview of 27 systematic reviews in women found cranberry among the non-antibiotic options supported for reducing recurrent UTIs, though the authors noted questions remain about optimal dose and duration. It is class-level cranberry evidence, not a trial of the Cranmax product.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — cranberry is well tolerated.
Mild digestive upset is occasionally reported.
Very high intake may slightly increase the risk of kidney stones in susceptible people.

Important Drug interactions

Warfarin — cranberry may interact; monitor INR if combined.
Tell your doctor if you have a history of kidney stones.
Not a substitute for antibiotics in an active infection; see a doctor for symptoms.

Frequently asked questions about Cranmax® (Whole Cranberry Concentrate, Decas)

What is Cranmax?

Cranmax® is a whole-fruit cranberry (Vaccinium macrocarpon) concentrate from Decas Botanical Synergies, capturing the cranberry's juice, seeds, and skin. Cranberry is best known for supporting urinary tract health, largely through compounds that help keep bacteria from sticking to the bladder wall.

What is Cranmax used for?

Cranmax is researched primarily for Kidney/Urinary Tract and Women's Health. Cranberry is widely used and studied for supporting urinary tract health and reducing the recurrence of urinary tract infections, a benefit recognized in reviews of non-antibiotic options.

What is the recommended dosage of Cranmax?

The clinically studied dose is Commonly 500 mg of cranberry concentrate per day. Always follow the product label and check with a healthcare provider for personal advice.

Is Cranmax safe, and does it have side effects?

For most healthy adults, Cranmax is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — cranberry is well tolerated. Mild digestive upset is occasionally reported. It may also interact with some medications. Cranmax is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Cranmax interact with any medications?

Possible interactions include: Warfarin — cranberry may interact; monitor INR if combined. Tell your doctor if you have a history of kidney stones. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Cranmax?

NutraSmarts rates the evidence for Cranmax as Limited (2 out of 5). It is backed by 1 clinical trial and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Santer M, Miller S, Fraser S, et al. Non-antibiotic interventions to prevent recurrent urinary tract infections in women: overview of systematic reviews of randomised controlled trials. Br J Gen Pract. 2026;(advance)..PubMedUsed to support: Overview of systematic reviews of randomized trials of non-antibiotic options to prevent recurrent UTIs in women. It lists cranberry among the supported non-antibiotic options while noting questions remain about optimal dose and duration. This is high-level, generic-cranberry evidence, not a trial of the Cranmax product.
  2. Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;11(11):CD001321. doi: 10.1002/14651858.CD001321.pub7.PubMedUsed to support: Systematic review of 50 randomised trials (8,857 participants). Cranberry products reduced the risk of symptomatic, culture-verified UTIs in women with recurrent UTIs, in children, and in people susceptible to UTIs after procedures (moderate certainty). The evidence did not support use in the elderly, people with bladder-emptying problems, or pregnant women. This is generic-cranberry evidence, not specific to the Cranmax product.
  3. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to CranMax and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2014;12(5):3657. doi: 10.2903/j.efsa.2014.3657.PubMedUsed to support: European regulators evaluated CranMax by name and concluded that a cause-and-effect relationship has not been established between consumption of CranMax and reduction of the risk of urinary tract infection through bacterial anti-adhesion. This is the only Cranmax-brand-specific regulatory assessment located, and its result was negative.